Xenetic Biosciences Inc

Change company Symbol lookup

Select an option...

XBIO Xenetic Biosciences Inc

TBCPW Thunder Bridge Capital Partners III Equity Warrant Exp 01 Feb 2025 *W EXP 02/01/2025

HGKGY Power Assets Holdings Ltd

ICPT Intercept Pharmaceuticals Inc

KEY KeyCorp

TTWO Take-Two Interactive Software Inc

TOPS Top Ships Inc

BOLT Bolt Biotherapeutics Inc

ACET Adicet Bio Inc

VCNX Vaccinex Inc

Go

Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing its immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are weblike structures composed of extracellular chromatin coated with histones and other proteins. The Company is also developing its personalized Chimeric Antigen Receptor (CAR) T platform technology, XCART, to develop cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. It is also focused on developing its proprietary drug delivery platform, PolyXen, which uses the biological polymer polysialic acid (PSA) to prolong the drug's half-life and potentially improve the stability of therapeutic peptides and proteins.